Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients

被引：51
作者：
D'Avolio, A [1 ]
Ibañez, A [1 ]
Sciandra, M [1 ]
Siccardi, M [1 ]
de Requena, DG [1 ]
Bonora, S [1 ]
Di Perri, G [1 ]
机构：
[1] Univ Turin, Amedeo Savoia Hosp, Dept Infect Dis, I-16410149 Turin, Italy
来源：
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2006年 / 835卷 / 1-2期
关键词：
ribavirin; liquid/liquid; HPLC; UV method;
D O I：
10.1016/j.jchromb.2006.03.019
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Measurement of ribavirin plasma levels in HCV-positive patients have been shown to be useful in order to optimise individual ribavirin exposure. Efficacy and toxicity of this drug are shown to be concentration-dependant. A simple HPLC-UV method was developed and validated, which has an easy liquid/liquid extraction, sensitive limit of detection, without any interference peaks, reproducible and linear over the range of clinical relevant concentrations. The assay warrants further evaluation as a tool for ribavirin therapeutic drug monitoring in HCV-positive patients. (c) 2006 Published by Elsevier B.V.
引用
收藏
页码：127 / 130
页数：4
相关论文
共 24 条
  • [1] Determination of ribavirin in human serum and plasma by capillary electrophoresis
    Breadmore, MC
    Theurillat, R
    Thormann, W
    [J]. ELECTROPHORESIS, 2004, 25 (10-11) : 1615 - 1622
  • [2] Dosage of ribavirin in patients with Hepatitis C should be based on renal function:: A population pharmacokinetic analysis
    Bruchfeld, A
    Lindahl, K
    Schvarcz, R
    Ståhle, L
    [J]. THERAPEUTIC DRUG MONITORING, 2002, 24 (06) : 701 - 708
  • [3] The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase
    Cameron, CE
    Castro, C
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2001, 14 (06) : 757 - 764
  • [4] Treatment of chronic hepatitis C: A systematic review
    Chander, G
    Sulkowski, MS
    Jenckes, MW
    Torbenson, MS
    Herlong, HF
    Bass, EB
    Gebo, KA
    [J]. HEPATOLOGY, 2002, 36 (05) : S135 - S144
  • [5] Chiaramonte M, 1999, CANCER-AM CANCER SOC, V85, P2132, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2132::AID-CNCR6>3.3.CO
  • [6] 2-8
  • [7] Ribavirin's antiviral mechanism of action: lethal mutagenesis?
    Crotty, S
    Cameron, C
    Andino, R
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (02): : 86 - 95
  • [8] Mechanism of action of interferon and ribavirin in treatment of hepatitis C
    Feld, JJ
    Hoofnagle, JH
    [J]. NATURE, 2005, 436 (7053) : 967 - 972
  • [9] A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
    Glue, P
    Rouzier-Panis, R
    Raffanel, C
    Sabo, R
    Gupta, SK
    Salfi, M
    Jacobs, S
    Clement, RP
    [J]. HEPATOLOGY, 2000, 32 (03) : 647 - 653
  • [10] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY (HPLC) ASSAY FOR RIBAVIRIN AND COMPARISON OF THE HPLC ASSAY WITH RADIOIMMUNOASSAY
    GRANICH, GG
    KROGSTAD, DJ
    CONNOR, JD
    DESROCHERS, KL
    SHERWOOD, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) : 311 - 315
123